What happens when you take rivaroxaban with fish oil?
Rivaroxaban (Xarelto) is a direct oral anticoagulant that blocks Factor Xa, a key enzyme in the clotting cascade. Fish oil is a dietary supplement rich in the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). EPA in particular is incorporated into platelet membranes, where it shifts production from thromboxane A2 (a potent platelet activator) toward thromboxane A3, which has much weaker pro-clotting effects.
At supplement doses, omega-3s mildly lengthen bleeding time, modestly inhibit platelet aggregation, and at high doses can lower fibrinogen and several clotting factors. Combined with rivaroxaban, the two work through different but complementary pathways: rivaroxaban suppresses thrombin generation, while fish oil dampens platelet activation. The net effect is a small additive increase in bleeding tendency.
Why is this important?
The clinical literature on this combination is actually reassuring at typical supplement doses. Recent reviews and FDA labeling for prescription omega-3 products (Lovaza, Vascepa) note that omega-3s do not produce clinically significant bleeding even when taken with antiplatelet or anticoagulant drugs. A retrospective study of patients on aspirin plus clopidogrel found that adding roughly 3 g of fish oil did not increase major or minor bleeding compared with the dual antiplatelet alone.
However, the strongest data are for aspirin and warfarin combinations. Fewer studies have specifically examined DOACs like rivaroxaban. The mechanism (added platelet inhibition) is the same, so prescribers extrapolate cautiously. High-dose fish oil (over 3 to 4 g of combined EPA+DHA daily) is where the bleeding signal becomes noticeable, particularly in older adults, those on additional bleeding-risk drugs (NSAIDs, SSRIs), and patients with kidney impairment that raises rivaroxaban exposure.
What should you do?
Tell your prescribing clinician exactly which fish oil product you take and the daily dose of EPA+DHA (not just the total capsule weight, which usually overstates the active content). Most over-the-counter fish oil softgels supply 300 to 500 mg of combined EPA+DHA per capsule, so two a day is well below the threshold of concern.
If you take prescription-strength omega-3s such as Lovaza (4 g/day of EPA+DHA ethyl esters) or Vascepa (4 g/day of pure EPA), or if you take more than 3 g of EPA+DHA from supplements, you and your prescriber should weigh whether the cardiovascular benefit outweighs the small added bleeding risk on rivaroxaban.
Stop fish oil at least 7 days before elective surgery, major dental work, or epidural injections, unless your surgeon advises otherwise. Watch for: easy bruising, nosebleeds that take more than 10 minutes to stop, bleeding gums, pink or red urine, dark or tarry stools, persistent headache, or unexplained weakness. These warrant immediate evaluation.
Which specific products are affected?
This applies to rivaroxaban under any brand name (Xarelto) at any dose. On the omega-3 side it covers regular fish oil softgels, liquid fish oil, krill oil, algae-based EPA/DHA, cod liver oil, and prescription omega-3s (icosapent ethyl/Vascepa, omega-3 acid ethyl esters/Lovaza, Omtryg, Epanova). It also applies to many heart-health, prenatal, and joint-health multi-supplements that contain hidden omega-3s.
The same principles apply to the other DOACs (apixaban, edoxaban, dabigatran) and to warfarin, though warfarin requires INR monitoring rather than visual bleed-watching.
The bottom line
Low to moderate fish oil doses (under about 1 g of EPA+DHA per day) are generally considered safe alongside rivaroxaban and may even provide cardiovascular benefit. Doses above 3 g, prescription omega-3s, or combinations with other bleeding-risk drugs deserve a conversation with your prescriber. Always disclose your supplement use, know the bleeding warning signs, and stop fish oil before any planned procedure.